The results of a Phase I clinical study (NCT02349724), employing carcino-embryonic antigen (CEA)-CAR-T therapy administered systemically through intravenous infusion to treat patients with CRC, revealed an absence of sustained therapeutic effects [9]. Here, CEACAM5 is linked to colorectal carcinoma.